Neurology/psychiatricRAG-17 silences SOD1, extends survival in ALS preclinical modelsResearchers from Ractigen Therapeutics Co. Ltd. described the preclinical profile of RAG-17, an siRNA therapy designed to knockdown the expression of SOD1, conjugated to a smart chemistry aided delivery (SCAD) system for enhanced CNS delivery via intrathecal injection.